Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
Alkermes CEO Blair Jackson said the company expects clinical readouts across its orexin programs in sleep disorders, ADHD and fatigue over the next 12 months. The headline also notes a LUMRYZ filing is ahead.
Why it matters — The anticipated readouts and filing are upcoming developments for ALKS watchers to follow.